ADAR1 Capital Management LLC Increases Stake in Astria Therapeutics, Inc. $ATXS

Key Points

• ADAR1 Capital Management LLC significantly increased its holdings in Astria Therapeutics by 605.3%, owning approximately 641,690 shares valued at $3.43 million as of the last quarter.
• Several institutional investors, including GAMMA Investing LLC and Brooklyn Investment Group, also made substantial increases in their positions in Astria Therapeutics, highlighting strong interest in the stock.
• Astria Therapeutics has a market capitalization of $348.80 million and has received positive ratings from analysts, with an average rating of "Buy" and a consensus price target of $29.00.

ADAR1 Capital Management LLC raised its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 605.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 641,690 shares of the biotechnology company's stock after purchasing an additional 550,706 shares during the quarter. ADAR1 Capital Management LLC owned approximately 1.14% of Astria Therapeutics worth $3,427,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of ATXS. PDT Partners LLC raised its stake in Astria Therapeutics by 173.2% in the first quarter. PDT Partners LLC now owns 28,707 shares of the biotechnology company's stock valued at $153,000 after purchasing an additional 18,200 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Astria Therapeutics by 503.7% in the first quarter. Cubist Systematic Strategies LLC now owns 92,239 shares of the biotechnology company's stock worth $493,000 after purchasing an additional 76,961 shares during the last quarter. DAFNA Capital Management LLC grew its holdings in shares of Astria Therapeutics by 5.0% in the first quarter. DAFNA Capital Management LLC now owns 314,775 shares of the biotechnology company's stock worth $1,681,000 after purchasing an additional 15,000 shares during the last quarter. Jump Financial LLC bought a new position in shares of Astria Therapeutics in the first quarter worth approximately $178,000. Finally, AlphaQuest LLC boosted its holdings in Astria Therapeutics by 100.9% in the first quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 7,139 shares in the last quarter. 98.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on ATXS. Citigroup reissued an "outperform" rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a research report on Wednesday, May 14th. Finally, JMP Securities upped their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, Astria Therapeutics has a consensus rating of "Buy" and an average price target of $29.00.

Astria Therapeutics Trading Up 7.4%

Shares of ATXS stock traded up $0.52 on Friday, reaching $7.52. The company's stock had a trading volume of 542,624 shares, compared to its average volume of 271,053. The company has a market capitalization of $424.43 million, a price-to-earnings ratio of -3.74 and a beta of 0.42. The stock's fifty day simple moving average is $6.50 and its 200-day simple moving average is $5.70. Astria Therapeutics, Inc. has a 1 year low of $3.56 and a 1 year high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.04. Equities research analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.